<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10944599</article-id><article-id pub-id-type="pmc">2363501</article-id><article-id pub-id-type="pii">6691338</article-id><article-id pub-id-type="doi">10.1054/bjoc.2000.1338</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>The treatment of Wilms' tumour: results of the United Kingdom Children's Cancer Study Group (UKCCSG) second Wilms' tumour study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mitchell</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Jones</surname><given-names>P Morris</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kelsey</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Vujanic</surname><given-names>G M</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Marsden</surname><given-names>B</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Shannon</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Gornall</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Owens</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Taylor</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Imeson</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Middleton</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Pritchard</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff9">9</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Paediatric Oncology, Oxford Radcliffe Hospital, Oxford, OX 9DU</aff><aff id="aff2"><label>2</label>Royal Manchester Children&#x02019;s Hospital, Pendlebury, Manchester, M27 1HA</aff><aff id="aff3"><label>3</label>Department of Histopathology, University of Wales College of Medicine, Cardiff, CF4 4XN</aff><aff id="aff4"><label>4</label>Paediatric Oncology, Leicester Royal Infirmary, Leicester, LE1 5WW</aff><aff id="aff5"><label>5</label>Department of Surgery, Birmingham Children&#x02019;s Hospital, Birmingham, B4 6NH</aff><aff id="aff6"><label>6</label>Department of Radiology, Great Ormond Street Hospital for Children, London, WC1N 3JH</aff><aff id="aff7"><label>7</label>Cookridge Hospital, Leeds, LS16 6QB</aff><aff id="aff8"><label>8</label>UKCCSG Data Centre, University of Leicester, Leicester, LE1 6TP</aff><aff id="aff9"><label>9</label>Institute of Child Health, Guilford Street, London, WC1 N3 JH, UK</aff><pub-date pub-type="epub"><day>16</day><month>08</month><year>2000</year></pub-date><pub-date pub-type="ppub"><month>09</month><year>2000</year></pub-date><volume>83</volume><issue>5</issue><fpage>602</fpage><lpage>608</lpage><history><date date-type="received"><day>18</day><month>11</month><year>1999</year></date><date date-type="rev-recd"><day>04</day><month>05</month><year>2000</year></date><date date-type="accepted"><day>17</day><month>05</month><year>2000</year></date></history><copyright-statement>Copyright 2000, Cancer Research Campaign</copyright-statement><copyright-year>2000</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>The aims of the UKW2 study were: (1) to further refine treatment for stage I and II favourable histology (FH) patients; (2) to consolidate the UKW1 results for stage III FH patients; (3) to improve the outlook for patients with inoperable primary tumours and those patients with stage IV and unfavourable histology disease. Treatment consisted of primary nephrectomy, wherever possible, followed by chemotherapy and radiotherapy, as dictated by stage and histology. Treatment was refined successfully for stage I and II FH patients. The 4-year event-free survival for these two groups was 94&#x00025; and 91&#x00025;, respectively. Stage III FH patients had a 4-year event free survival of 84&#x00025;. The outlook for patients with clear cell sarcoma of the kidney is as good as for patients with favourable histology, whilst that for patients with anaplastic or rhabdoid variants remains poor. The outlook for the majority of children with Wilms&#x02019; tumour is now excellent. &#x000a9; 2000 Cancer Research Campaign</p></abstract><kwd-group><kwd>Wilms&#x02019;</kwd><kwd>tumour</kwd><kwd>treatment</kwd><kwd>chemotherapy</kwd><kwd>radiotherapy</kwd><kwd>childhood cancer</kwd></kwd-group></article-meta></front></article>


